Glionova

About:

Glionova is a privately held biopharmaceutical company focused on developing new therapies for cancer.

Twitter/X: glionova

Top Investors: Novo Holdings, Industrifonden, HealthCap

Description:

Glionova AB, a development stage biopharmaceutical company, is engaged in the development of therapies for difficult-to-treat cancers. The company develops GLN-1001, an orally bioavailable small molecule that induces selective cell death in glioblastoma cells without causing harm to normal brain tissue.

Total Funding Amount:

$5.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Stockholm, Stockholms Lan, Sweden

Founded Date:

2014-01-01

Founders:

Lars Hammarström

Number of Employees:

1-10

Last Funding Date:

2014-12-09

IPO Status:

Private

Industries: